Details for Patent: 8,188,104
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 8,188,104 protect, and when does it expire?
Patent 8,188,104 protects VIEKIRA XR and VIEKIRA PAK (COPACKAGED) and is included in two NDAs.
This patent has forty-five patent family members in twenty-one countries.
Summary for Patent: 8,188,104
Title: | Anti-infective agents and uses thereof |
Abstract: | This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. |
Inventor(s): | Flengte; Charles A. (Salem, WI), Hutchinson; Douglas K. (Antioch, IL), Betebenner; David A. (Libertyville, IL), DeGoey; David A. (Salem, WI), Donner; Pamela L. (Mundelein, IL), Kati; Warren M. (Gurnee, IL), Krueger; Allan C. (Gurnee, IL), Liu; Dachun (Waukegan, IL), Liu; Yaya (Buffalo Grove, IL), Longenecker; Kenton L. (Grayslake, IL), Maring; Clarence J. (Palatine, IL), Motter; Christopher E. (Oak Creek, WI), Pratt; John K. (Kenosha, WI), Randolph; John T. (Libertyville, IL), Rockway; Todd W. (Grayslake, IL), Stewart; Kent D. (Gurnee, IL), Wagner; Rolf (Antioch, IL), Chen; Shuang (Gurnee, IL), Gao; Yi (Vernon Hills, IL), Lou; Xiaochun (Long Grove, IL), Zhang; Geoff G. Z. (Libertyville, IL) |
Assignee: | Abbott Laboratories (Abbott Park, IL) |
Application Number: | 12/212,323 |
Patent Claim Types: see list of patent claims | Compound; Composition; Use; |
Drugs Protected by US Patent 8,188,104
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie Inc | VIEKIRA XR | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, EXTENDED RELEASE;ORAL | 208624-001 | Jul 22, 2016 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION. | See Plans and Pricing | ||
Abbvie Inc | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir | TABLET;ORAL | 206619-001 | Dec 19, 2014 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION. | See Plans and Pricing | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,188,104
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 519746 | See Plans and Pricing | |||
Canada | 2699986 | See Plans and Pricing | |||
Canada | 2849420 | See Plans and Pricing | |||
China | 101842360 | See Plans and Pricing | |||
China | 102746240 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |